{"id":32010,"date":"2025-04-18T13:52:40","date_gmt":"2025-04-18T05:52:40","guid":{"rendered":"https:\/\/flcube.com\/?p=32010"},"modified":"2025-04-18T13:52:41","modified_gmt":"2025-04-18T05:52:41","slug":"shanghai-henlius-initiates-phase-ii-study-of-hlx22-in-her2-low-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32010","title":{"rendered":"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer"},"content":{"rendered":"\n<p>China-based Shanghai Henlius Biotech Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) has announced the first patient dosing in a Phase II study assessing the efficacy and safety of its HER2-targeted monoclonal antibody (mAb) HLX22 combined with trastuzumab deruxtecan. The study focuses on patients with HR-positive, HER2 low-expressing locally advanced or metastatic breast cancer who have experienced disease progression or intolerable toxic reactions following standard treatment.<\/p>\n\n\n\n<p><strong>HLX22: Development and Applications<\/strong><br>HLX22, licensed from AbClon, Inc., is under development for the treatment of gastric cancer, breast cancer, and other solid tumors. This Phase II study marks a significant step in evaluating its potential in combination therapies for breast cancer, particularly in the HER2 low-expressing patient population.<\/p>\n\n\n\n<p><strong>Clinical Trial and Future Outlook<\/strong><br>The initiation of this Phase II study highlights Henlius\u2019s commitment to advancing innovative therapies for patients with limited treatment options. By combining HLX22 with trastuzumab deruxtecan, the trial aims to explore new treatment paradigms for advanced breast cancer, potentially improving outcomes for this challenging patient group.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025041700912_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025041700912_c.\"><\/object><a id=\"wp-block-file--media-0d0ec737-3f06-4c20-b032-c8aa11385fb6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025041700912_c.pdf\">2025041700912_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025041700912_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0d0ec737-3f06-4c20-b032-c8aa11385fb6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32012,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,270,862],"class_list":["post-32010","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-henlius-biotech","tag-hkg-2696"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a Phase II study assessing the efficacy and safety of its HER2-targeted monoclonal antibody (mAb) HLX22 combined with trastuzumab deruxtecan. The study focuses on patients with HR-positive, HER2 low-expressing locally advanced or metastatic breast cancer who have experienced disease progression or intolerable toxic reactions following standard treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32010\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a Phase II study assessing the efficacy and safety of its HER2-targeted monoclonal antibody (mAb) HLX22 combined with trastuzumab deruxtecan. The study focuses on patients with HR-positive, HER2 low-expressing locally advanced or metastatic breast cancer who have experienced disease progression or intolerable toxic reactions following standard treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32010\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-18T05:52:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T05:52:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1804.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer\",\"datePublished\":\"2025-04-18T05:52:40+00:00\",\"dateModified\":\"2025-04-18T05:52:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010\"},\"wordCount\":181,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1804.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Henlius Biotech\",\"HKG: 2696\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32010#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32010\",\"name\":\"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1804.webp\",\"datePublished\":\"2025-04-18T05:52:40+00:00\",\"dateModified\":\"2025-04-18T05:52:41+00:00\",\"description\":\"China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a Phase II study assessing the efficacy and safety of its HER2-targeted monoclonal antibody (mAb) HLX22 combined with trastuzumab deruxtecan. The study focuses on patients with HR-positive, HER2 low-expressing locally advanced or metastatic breast cancer who have experienced disease progression or intolerable toxic reactions following standard treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32010\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1804.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1804.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32010#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a Phase II study assessing the efficacy and safety of its HER2-targeted monoclonal antibody (mAb) HLX22 combined with trastuzumab deruxtecan. The study focuses on patients with HR-positive, HER2 low-expressing locally advanced or metastatic breast cancer who have experienced disease progression or intolerable toxic reactions following standard treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32010","og_locale":"en_US","og_type":"article","og_title":"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer","og_description":"China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a Phase II study assessing the efficacy and safety of its HER2-targeted monoclonal antibody (mAb) HLX22 combined with trastuzumab deruxtecan. The study focuses on patients with HR-positive, HER2 low-expressing locally advanced or metastatic breast cancer who have experienced disease progression or intolerable toxic reactions following standard treatment.","og_url":"https:\/\/flcube.com\/?p=32010","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-18T05:52:40+00:00","article_modified_time":"2025-04-18T05:52:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1804.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32010#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32010"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer","datePublished":"2025-04-18T05:52:40+00:00","dateModified":"2025-04-18T05:52:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32010"},"wordCount":181,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32010#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1804.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Henlius Biotech","HKG: 2696"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32010#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32010","url":"https:\/\/flcube.com\/?p=32010","name":"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32010#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32010#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1804.webp","datePublished":"2025-04-18T05:52:40+00:00","dateModified":"2025-04-18T05:52:41+00:00","description":"China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a Phase II study assessing the efficacy and safety of its HER2-targeted monoclonal antibody (mAb) HLX22 combined with trastuzumab deruxtecan. The study focuses on patients with HR-positive, HER2 low-expressing locally advanced or metastatic breast cancer who have experienced disease progression or intolerable toxic reactions following standard treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32010#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32010"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32010#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1804.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1804.webp","width":1080,"height":608,"caption":"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32010#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1804.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32010"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32010\/revisions"}],"predecessor-version":[{"id":32013,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32010\/revisions\/32013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32012"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}